These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10565996)

  • 21. Antisense oligodeoxynucleotides for organ transplantation.
    Stepkowski SM
    Clin Biochem; 1998 Jul; 31(5):375-9. PubMed ID: 9721437
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
    J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.
    Marshall JL; Eisenberg SG; Johnson MD; Hanfelt J; Dorr FA; El-Ashry D; Oberst M; Fuxman Y; Holmlund J; Malik S
    Clin Colorectal Cancer; 2004 Nov; 4(4):268-74. PubMed ID: 15555210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHH 380. Chimeric anti-CD7 antibody, SDZ CHH 380.
    Drugs R D; 1999 Jan; 1(1):73-4. PubMed ID: 10565992
    [No Abstract]   [Full Text] [Related]  

  • 25. Antisense oligonucleotides in lung cancer.
    Pujol JL; Jacot W
    Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract]   [Full Text] [Related]  

  • 26. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 27. Campath-1G. Campath IgG, Campath-1-IgG antibody.
    Drugs R D; 1999 Jan; 1(1):71-2. PubMed ID: 10565991
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
    Leeds JM; Henry SP; Geary R; Burckin T; Levin AA
    Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):435-41. PubMed ID: 11198927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR; Bowen-Yacyshyn MB; Jewell L; Tami JA; Bennett CF; Kisner DL; Shanahan WR
    Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biotech comes to its 'antisenses' after hard-won drug approval.
    Jiang K
    Nat Med; 2013 Mar; 19(3):252. PubMed ID: 23467223
    [No Abstract]   [Full Text] [Related]  

  • 31. Leflunomide. Arava, HWA 486, SU 101.
    Drugs R D; 1999 Jan; 1(1):87-91. PubMed ID: 10565997
    [No Abstract]   [Full Text] [Related]  

  • 32. Alicaforsen therapy in inflammatory bowel disease.
    Barish CF
    Expert Opin Biol Ther; 2005 Oct; 5(10):1387-91. PubMed ID: 16197343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
    Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
    Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
    Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA
    Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
    Rao S; Watkins D; Cunningham D; Dunlop D; Johnson P; Selby P; Hancock BW; Fegan C; Culligan D; Schey S; Morris TC; Lissitchkov T; Oliver JW; Holmlund JT
    Ann Oncol; 2004 Sep; 15(9):1413-8. PubMed ID: 15319248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
    Watanabe TA; Geary RS; Levin AA
    Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense oligonucleotide treatment of inflammatory bowel diseases.
    Yacyshyn BR
    Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
    [No Abstract]   [Full Text] [Related]  

  • 38. Inolimomab. Anti-CD25 monoclonal antibody B-B10, anti-interleukin-2 receptor monoclonal antibody B-B10, B-B10, BT 563, Leukotac.
    Drugs R D; 1999 Jan; 1(1):81-4. PubMed ID: 10565995
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
    Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
    J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
    Oza AM; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund JT; Eisenhauer E;
    Gynecol Oncol; 2003 Apr; 89(1):129-33. PubMed ID: 12694666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.